DNTH — Dianthus Therapeutics, Inc. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1690585 ·
Last close
$88.55
Market Cap
$4.95B
52W High
$117.88
52W Low
$32.22
ADV30
758,830
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 761,000 | — | -61,482,000 | -50,215,000 | 1,213,271,000 | 110,549,000 | 41,246,000 |
| Mar 2026 | 463,000 | — | -46,533,000 | -40,834,000 | 1,246,884,000 | 627,667,000 | 45,570,000 |
| Dec 2025 | 284,000 | — | -69,541,000 | -64,432,000 | 530,922,000 | 51,087,000 | 37,521,000 |
| Sep 2025 | 396,000 | — | -40,288,000 | -36,765,000 | 577,445,000 | 55,984,000 | 30,991,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-155,375,000
Investing CF
$-776,562,000
Financing CF
$1,029,186,000
CapEx
$-334,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.15
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-427,778,000
Inventory
—
Receivables
$106,000
ST Investments
$776,264,000
EBIT TTM
$-217,844,000
Pretax Income TTM
$-192,246,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,904,000
EBITDA
$-217,720,992
Free Cash Flow
$-92,210,496
Enterprise Value
$5,054,705,152
Total Cash
$886,812,992
Total Debt
$1,287,000
Shares Out
55,934,378
Trailing EPS
$-4.24
Book Value
$21.39
ROE
-26.1%
ROA
-17.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,036,000 | -177,933,000 | -162,337,000 | 530,922,000 | 37,521,000 | 493,401,000 | -129,060,000 |
| Dec 2024 | 6,235,000 | -101,864,000 | -84,969,000 | 374,008,000 | 21,531,000 | 352,477,000 | -78,180,000 |
| Dec 2023 | 2,826,000 | -48,174,000 | -43,555,000 | 179,405,000 | 10,535,000 | 168,870,000 | -36,861,000 |
| Dec 2022 | 6,417,000 | -29,705,000 | -28,476,000 | 83,110,000 | 9,454,000 | 73,656,000 | -29,070,000 |
TTM Snapshot
Revenues TTM
$1,163,000
NetIncome TTM
$-29,511,000
OpCashFlow TTM
$0
Assets (Latest)
$530,922,000
Forward EPS
$-4.61
Max Pain — expiry 2026-11-20
max pain strike: $80.00 · spot: $88.01 · call oi: 5,611 · put oi: 27Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERAS | Erasca, Inc. | $4.98B | $14.25 | — |
| MANE | Veradermics, Inc | $4.87B | $116.57 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.23B | $62.67 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.59B | $84.46 | — |
| TVTX | Travere Therapeutics, Inc. | $5.60B | $59.44 | — |
News headlines (Yahoo Finance, 1h cache)
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
2026-09-24 08:10 · Yahoo
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run
2026-09-24 02:12 · Yahoo
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
2026-09-05 11:30 · Yahoo
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 21:00 · Yahoo
Dianthus Therapeutics to Participate in Three Investor Conferences During September
2026-09-01 12:00 · Yahoo
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
2026-08-04 20:01 · Yahoo
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
2026-08-04 11:00 · Yahoo
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
2026-07-02 20:01 · Yahoo
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
2026-06-29 11:00 · Yahoo
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
2026-06-15 11:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.